Sofinnova secures $750M for eleventh fund focused on drugmakers nearing the clinicnews2025-11-17T01:01:20+00:00November 17th, 2025|Endpoints News|
Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and morenews2025-11-15T11:00:13+00:00November 15th, 2025|Endpoints News|
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing studynews2025-11-14T20:48:04+00:00November 14th, 2025|Endpoints News|
Onshoring and data ‘fidelity’: What FDA wants from generic drug user fee talksnews2025-11-14T20:47:05+00:00November 14th, 2025|Endpoints News|
CHMP endorses Sanofi diabetes drug, Lilly breast cancer treatmentnews2025-11-14T19:42:51+00:00November 14th, 2025|Endpoints News|
Zhejiang Doer Biologics unveils first-in-class tri-agonist for high lipidsnews2025-11-14T17:56:23+00:00November 14th, 2025|Endpoints News|
Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XInews2025-11-14T16:16:30+00:00November 14th, 2025|Endpoints News|
Pfizer reduces stake in BioNTech; Candel pauses pancreatic cancer programnews2025-11-14T16:06:15+00:00November 14th, 2025|Endpoints News|
Cartesian to pause work in form of lupus, despite trial successnews2025-11-14T15:48:11+00:00November 14th, 2025|Endpoints News|
Exclusive: The inside story of Pfizer and Novo’s fight for the $10B Metsera dealnews2025-11-14T14:00:19+00:00November 14th, 2025|Endpoints News|
